TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04017572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Automated peritoneal dialysis (APD)
Description: Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Automated peritoneal dialysis (APD)
Description: Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
Study: NCT02524275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03172884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (ALIQOPA, BAY80-6946)
Description: 12mg single dose, intravenous on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (ALIQOPA, BAY80-6946)
Description: 12mg single dose, intravenous on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (ALIQOPA, BAY80-6946)
Description: 12mg single dose, intravenous on Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (ALIQOPA, BAY80-6946)
Description: 12mg single dose, intravenous on Day 0
Study: NCT00467194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT04418492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills for Adaptive Functioning through Executive training (SAFE; tentative title)
Description: An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
Study: NCT01037725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD5847
Description: In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
Study: NCT04470804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus treats in experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Cyclosporine A uses for active comparator group.
Study: NCT03772834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo resistance training and walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo resistance training and walking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Undergo stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Undergo stretching
Study: NCT03760887

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home exercise program only
Description: After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program and home program of sensory discrimination
Description: After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
Study: NCT00519324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg/day (2 tablets of 5 mg each)
Study: NCT02985190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at 75mg/m²/j for 7 days.
Study: NCT02991326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~* Compression of the fourth ventricle;~* inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~* inhibition of the inferior head of the lateral pterygoid muscle;~* intra-oral inhibition of the masseter muscle;~* Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~* BLT of the accessory ligaments - pterygomandibular raphe;~* sphenopalatine ganglion technique;~* Craniosacral rebalancing;

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
Study: NCT02021357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperbolid combined with tongue exercises on the palate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperbolid
Study: NCT00156208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10mg Tablet, oral Daily for 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 18 months
Study: NCT03683030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Electrode RF Balloon Catheter
Description: Multi-Electrode RF Balloon Catheter will be inserted
Study: NCT04516759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 50mg film-coated tablets (at daily dose of 100mg BID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets
Study: NCT00174252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotonorm (Somatropin)
Description: 0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
Study: NCT06395571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Goat milk-based infant formula fed at age appropriate quantities for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk-based infant formula
Description: Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
Study: NCT01182649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coronary stent
Description: coronary angioplasty with stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: coronary angioplasty with stent implantation
Study: NCT00811941

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study: NCT02377700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Vascular Patch, Model COR-VP-001
Description: The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
Study: NCT01318694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study: NCT02840474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB
Description: VRC01LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an investigational human monoclonal antibody targeted to the CD4+ binding site of HIV-1.
Study: NCT04051723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The ropivacaine
Description: The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study: NCT00187876

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction control
Description: The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
Study: NCT06796088

Intervention type: OTHER
Intervention: Treated zones exposed to Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Treated zones exposed to Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Treated zones exposed to Visible Light source
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.

Intervention type: OTHER
Intervention: Untreated zone exposed to Visible Light source
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study: NCT06794788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-The iWear
Description: The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-The iWear
Description: The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles
Study: NCT00025207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02701283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Transcatheter Aortic Valve Replacement Systems
Description: Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Description: Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
Study: NCT01258933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
Study: NCT02902302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/10 mL oral suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MOMENT 400 mg coated tablet
Study: NCT02712983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP and placebo
Description: TIP and inhaled placebo dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP and placebo
Description: TIP and inhaled placebo dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP and placebo
Description: TIP and inhaled placebo dose regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo dose regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo dose regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo dose regimen
Study: NCT02815657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
Study: NCT01457014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation auto
Description: Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation manual
Description: servo ventilation titrated in manual mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation manual
Description: servo ventilation titrated in manual mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: servo ventilation manual
Description: servo ventilation titrated in manual mode
Study: NCT01318694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study: NCT03922594

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Differential diagnosis for infectious causes of microcephaly
Description: Zika virus, cytomegalovirus, rubella, toxoplasmosis
Study: NCT00187876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Biocleanse, surgical
Description: The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
Study: NCT01384253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ²¹²Pb-TCMC-Trastuzumab
Description: The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg.
Study: NCT02670083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenezumab
Description: Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study: NCT01786798

Intervention type: DEVICE
Group type: OTHER
Intervention: Transvaginal sonography
Description: Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern
Study: NCT02870582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: treatment drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Best support treatment
Study: NCT01439191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized anti-HER2 antibody
Description: Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: humanized anti-HER2 antibody
Description: Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
Study: NCT02329353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 Lozenges
Description: Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 Lozenges
Description: Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
Study: NCT01318694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study: NCT03710538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack beverage
Description: Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Snack beverage
Description: Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3min walk at 60% VO2max every 30 minutes,(x5)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 3min walk at 60% VO2max every 30 minutes,(x5)
Study: NCT04506021

Intervention type: DRUG
Intervention: Bicarbonate Ringer's solution
Description: According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.

Intervention type: DRUG
Intervention: Other Crystalloid
Description: According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
Study: NCT00081484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa or beta
Description: iv or sc, as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks